TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
FDA expands indications for bupivacaine liposome injectable suspension (Exparel; Pacira BioSciences, Inc.) for use in adult patients as an adductor canal block and a sciatic nerve block in the ...
The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve ...
In both studies, Exparel achieved a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine hydrochloride. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback